Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2018 ASCO Annual Meeting but not presented at the Meeting, can be found online only.
Cannabis in cancer patients [CP] to improve quality of life [QOL] and cancer related symptoms [CRS]: Illinois Cancer Care cannabis education and clinical analysis.
Quality of Care/Quality Improvement
Health Services Research, Clinical Informatics, and Quality of Care
2018 ASCO Annual Meeting
J Clin Oncol 36, 2018 (suppl; abstr e18812)
Author(s): Shawn Michael Seibert, Pankaj Kumar, Patrick Leigh Gomez, Christina Nicole Gomez, Laura M. Miller, Matt Logsdon; Illinois Cancer Care, Peoria, IL; Illinois CancerCare, Peoria, IL; University of Missouri at Kansas City Medical Schoo, Peoria, IL
Background: Improvement [I] in [QOL] and CRS varies greatly with different cannabis products. Evidence supporting specific cannabis products and frequency of use to improve QOL and CRS is lacking. We at ILCC analyzed the effect of cannabis use in CP. We specifically evaluated its effect on anxiety, pain, insomnia, appetite, nausea/vomiting [N&V] and QOL. Methods: We conducted a retrospective analysis of a cannabis use in CP actively using cannabis at ILCC. Pts with IL Medical Marijuana [MM] license were given a 24 question survey at the time of a scheduled office visit. CP actively using MM were asked to complete the self reported survey once during this four month period. All consecutive cannabis survey results from 09/01/17-01/01/18 were analyzed. Survey categories were: 1. Frequency of use: multiple times/day, once daily, few times a week, a few times monthly, or rarely. 2. Type of product used: oral, cream, smoke, vapor pen, oil, or tincture. 3. Reason for cannabis use and if symptoms improved: Anxiety, insomnia, N&V, pain control, and poor appetite. 4. Improved QOL improved(yes or no). 5. Adverse reactions to MM(yes or no). Results: 91 CP completed the surveys. All pts reported an [I] in CRS. 87.9% reported I of QOL, 98% I in Anxiety, 92% I of Insomnia, 95% I in N&V, 94% I in Pain, and 92% I in Appetite. Most benefit [71.6%] was seen in pts who used cannabis either daily or multiple times/day. Product used by pts were: oral 54%, smoke 46%, oil 44%, vapor pen 31%, tincture 15%, and cream 12%. No pts reported adverse reactions. Conclusions: Our results suggest that regular use of Cannabis improves QOL and CRS in CP. Pts prefer oral cannabis more than other formulations. ILCC plans to conduct a prospective study to evaluate MM in CP.
Meeting: 2018 ASCO Annual Meeting Abstract No: 6520 First Author: Lisa Catherine Barbera